Related Experiment Videos
Evaluation of Optical Coherence Tomography Angiography Parameters following Intravitreal Ranibizumab Biosimilar in
Punita Kumari Sodhi1, Aman Singh Rana1, Divya Doddaiah1
1Vitreoretina Unit, Department of Ophthalmology, Guru Nanak Eye Centre, Maulana Azad Medical College, New Delhi, India.
Introduction:
Ranibizumab biosimilar (RbB) has emerged as a cost-effective treatment modality. There is paucity of literature on optical coherence tomography angiography (OCTA) parameters following use of RbB in DME.
Objective:
To evaluate OCTA parameters following intravitreal ranibizumab RbB in DME.
Methodology:
In an interventional study on treatment naïve eyes having DME, ocular examination for best-corrected visual acuity (BCVA), intraocular pressure (IOP), colour vision (CV) and contrast sensitivity (CS) was done. Further, optical coherence tomography (OCT) measured central foveal thickness (CFT). The OCTA imaging examined the foveal avascular zone (FAZ) and vessel density (VD) in six layers, including superficial capillary plexus (SCP), deep capillary plexus (DCP), outer retina (OR), outer retinal chorio-capillaries (ORCC), chorio-capillaries (CC) and choroid (C). Serum vascular endothelial growth factor-A (VEGF-A) levels were measured using an enzyme-linked immunosorbent assay (ELISA). One month after 0.5 mg/0.05 ml intravitreal injection of RbB, pre- and post-treatment parameters were compared.
Result:
The study involved 44 eyes of 30 DME patients having a mean age of 56.0±8.66 years. The mean serum VEGF A levels were 539.11±336.44 pg/ml. Following treatment, the mean CFT reduced from 461.50±173.06 to 348.09±153.02 microns (p <0.001). Distance BCVA improved significantly from a logMAR of 0.88±0.13 to 0.58±0.23 (p <0.001). The mean FAZ area, perimeter and circularity reduced from 0.21±0.21mm2, 2.43±1.32 mm, and 0.38±0.11 to 0.16±0.15 mm2 (p = 0.32), 2.32±1.27 mm (p = 0.71) and 0.36±0.12 (p = 0.47) respectively. The mean VD in SCP was 19.70±12.78, DCP 5±8.15, OR 1.80±3.91, ORCC 16.48±14.82, CC 9.11±11.44 and choroid was 20.09±18.06, and this increased to 23.63±17.62 (p = 0.24), 5.93±6.97 (p = 0.52), 2.77±4.97 (p = 0.08), 27.14±16.19 (p = 0.001), 17.60±15.64 (p = 0.002) and 29.05±17.95 (p = 0.011) respectively.
Conclusion:
Treatment with a single injection of RbB significantly improved BCVA and reduced CFT in patients with DME one month after treatment. All the FAZ features, including area, perimeter and circularity, reduced, and VD across multiple retino-choroidal layers increased.
